A hormone receptor called GPER1 is linked to longer survival in some glioblastoma patients
Original title: G-protein coupled estrogen receptor 1 (GPER1) expression improves survival of glioblastoma patients depending on sex and age: biological mechanisms and epigenetic regulation.
How far along is this research?
- Lab cells
- Animals
- Review
- Tested in people
This was tested in people. That is the most reliable kind of research we share.
This was lab cells and a look back at old patient records, not a treatment tried in people.
The short version
Patients whose tumors made more of one hormone receptor tended to live longer, mostly younger women.
What was studied. Researchers studied brain tumor data from two large public patient databases. They also grew brain tumor cells in a lab to see what this receptor does.
What they found. Higher levels of GPER1 went with longer overall survival. The link was strongest in women under the age of 55. In the lab, adding more of this receptor slowed tumor cell growth. The team also found 3 spots on the gene where chemical tags seemed to turn its activity down.
What this means, and what it doesn't
What it could mean: Nothing about your care changes because of this study. It points out one possible target that drug makers could look at later. Right now it mainly helps explain why glioblastoma: A glioma that is given grade 4. Grade 4 is the highest grade there is. The tumor grows fast. Treatment usually starts soon after it is found. It often means surgery, and then radiation and chemotherapy. See the glossary often behaves differently in men and women.
What it doesn't mean: This is not a treatment and not a cure. No drug was given to any patient here. The work was done in lab dishes and by looking back at old patient records. Nobody has tested this idea in a trial in people. It could take many years to know if it helps, and it may not. Do not change your treatment based on this.
Source: PubMed, September 25, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.